Blog
Daily evidence-led peptide research, regulatory news, expert digest and explainers. Every claim sourced; no AI tells.
Page 41
Doctor suspended over Ozempic to partner
A GMC tribunal suspended a UK doctor for prescribing Ozempic and Wegovy, both semaglutide, to her partner without disclosure.
Experts Issue GLP-1 Guidance for NET Care
A new expert consensus statement sets ground rules for using GLP-1 drugs like tirzepatide in neuroendocrine tumor patients.
Can incretins ease psoriasis inflammation?
A 2026 editorial asks whether tirzepatide-class incretin therapy quiets inflammation biologics leave behind in psoriasis. A hypothesis, not a trial result.
Semaglutide Plus Luseogliflozin for MASH
A small randomised trial tested adding the SGLT2 drug luseogliflozin to semaglutide for MASH. Here is what the numbers did and did not show.
Ozempic in Pro-Eating-Disorder Communities
A 2026 study finds Ozempic, a semaglutide brand, is normalized more than warned against in a pro-eating-disorder community on X.
Semaglutide and aspiration risk in surgery
New ultrasound data and case reports on semaglutide, retained gastric content and aspiration are reshaping the pre-surgery cessation question.
Tesamorelin and ipamorelin: side effects
Racing heart, flushing, and dizziness after combining tesamorelin and ipamorelin with TRT: what the evidence says and when to seek care.
Thymosin β4 curbs colitis in mouse study
A 2026 mouse study found thymosin beta-4, the peptide sold as TB-500, eased colitis and gut fibrosis through a newly proposed receptor pathway.
CJC-1295 and Ipamorelin, Explained
CJC-1295 and ipamorelin are unapproved growth-hormone-axis peptides. Here is what the evidence shows, and why we will not give you a starting dose.
CJC-1295 in sports medicine: the evidence
A 2026 UCLA scoping review found that CJC-1295's claimed benefits for musculoskeletal recovery and athletic performance remain unsubstantiated by human trials.
What is GEP44? A GLP-1/PYY explainer
GEP44 is an investigational peptide that pairs GLP-1 with peptide YY signalling to test whether weight loss can come with fewer GI side effects.
GLP-1 agonists and throat symptoms
A study of 617,000 patients found GLP-1 agonists are linked to cough, throat discomfort, and voice changes. Here is what the evidence shows and why.